HEADER PROTEIN TRANSPORT/INHIBITOR 12-JUL-22 8DNZ
TITLE CRYO-EM STRUCTURE OF THE HUMAN SEC61 COMPLEX INHIBITED BY APRATOXIN F
COMPND MOL_ID: 1;
COMPND 2 MOLECULE: PROTEIN TRANSPORT PROTEIN SEC61 SUBUNIT GAMMA;
COMPND 3 CHAIN: B;
COMPND 4 ENGINEERED: YES;
COMPND 5 MOL_ID: 2;
COMPND 6 MOLECULE: PROTEIN TRANSPORT PROTEIN SEC61 SUBUNIT BETA;
COMPND 7 CHAIN: C;
COMPND 8 ENGINEERED: YES;
COMPND 9 MOL_ID: 3;
COMPND 10 MOLECULE: PROTEIN TRANSPORT PROTEIN SEC61 SUBUNIT ALPHA ISOFORM 1;
COMPND 11 CHAIN: A;
COMPND 12 SYNONYM: SEC61 ALPHA-1;
COMPND 13 ENGINEERED: YES;
COMPND 14 MUTATION: YES;
COMPND 15 MOL_ID: 4;
COMPND 16 MOLECULE: APRATOXIN F PEPTIDE INHIBITOR;
COMPND 17 CHAIN: D
SOURCE MOL_ID: 1;
SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS;
SOURCE 3 ORGANISM_COMMON: HUMAN;
SOURCE 4 ORGANISM_TAXID: 9606;
SOURCE 5 GENE: SEC61G;
SOURCE 6 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA;
SOURCE 7 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM;
SOURCE 8 EXPRESSION_SYSTEM_TAXID: 7108;
SOURCE 9 EXPRESSION_SYSTEM_CELL_LINE: SF9;
SOURCE 10 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS;
SOURCE 11 EXPRESSION_SYSTEM_PLASMID: PFASTBAC;
SOURCE 12 MOL_ID: 2;
SOURCE 13 ORGANISM_SCIENTIFIC: HOMO SAPIENS;
SOURCE 14 ORGANISM_COMMON: HUMAN;
SOURCE 15 ORGANISM_TAXID: 9606;
SOURCE 16 GENE: SEC61B;
SOURCE 17 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA;
SOURCE 18 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM;
SOURCE 19 EXPRESSION_SYSTEM_TAXID: 7108;
SOURCE 20 EXPRESSION_SYSTEM_CELL_LINE: SF9;
SOURCE 21 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS;
SOURCE 22 EXPRESSION_SYSTEM_PLASMID: PFASTBAC;
SOURCE 23 MOL_ID: 3;
SOURCE 24 ORGANISM_SCIENTIFIC: HOMO SAPIENS;
SOURCE 25 ORGANISM_COMMON: HUMAN;
SOURCE 26 ORGANISM_TAXID: 9606;
SOURCE 27 GENE: SEC61A1, SEC61A;
SOURCE 28 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA;
SOURCE 29 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM;
SOURCE 30 EXPRESSION_SYSTEM_TAXID: 7108;
SOURCE 31 EXPRESSION_SYSTEM_CELL_LINE: SF9;
SOURCE 32 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS;
SOURCE 33 EXPRESSION_SYSTEM_PLASMID: PFASTBAC;
SOURCE 34 MOL_ID: 4;
SOURCE 35 ORGANISM_SCIENTIFIC: LYNGBYA BOUILLONII;
SOURCE 36 ORGANISM_TAXID: 207920
KEYWDS TRANSLOCON, INHIBITOR, PROTEIN TRANSLOCATION, PROTEIN TRANSPORT,
KEYWDS 2 PROTEIN TRANSPORT-INHIBITOR COMPLEX
EXPDTA ELECTRON MICROSCOPY
AUTHOR E.PARK,S.ITSKANOV
REVDAT 4 13-NOV-24 8DNZ 1 REMARK
REVDAT 3 15-NOV-23 8DNZ 1 LINK ATOM
REVDAT 2 06-SEP-23 8DNZ 1 JRNL
REVDAT 1 24-MAY-23 8DNZ 0
JRNL AUTH S.ITSKANOV,L.WANG,T.JUNNE,R.SHERRIFF,L.XIAO,N.BLANCHARD,
JRNL AUTH 2 W.Q.SHI,C.FORSYTH,D.HOEPFNER,M.SPIESS,E.PARK
JRNL TITL A COMMON MECHANISM OF SEC61 TRANSLOCON INHIBITION BY SMALL
JRNL TITL 2 MOLECULES.
JRNL REF NAT.CHEM.BIOL. V. 19 1063 2023
JRNL REFN ESSN 1552-4469
JRNL PMID 37169959
JRNL DOI 10.1038/S41589-023-01337-Y
REMARK 2
REMARK 2 RESOLUTION. 2.57 ANGSTROMS.
REMARK 3
REMARK 3 REFINEMENT.
REMARK 3 SOFTWARE PACKAGES : SERIALEM, WARP, CRYOSPARC, COOT,
REMARK 3 PHENIX, CRYOSPARC, CRYOSPARC, CRYOSPARC
REMARK 3 RECONSTRUCTION SCHEMA : FOURIER SPACE
REMARK 3
REMARK 3 EM MAP-MODEL FITTING AND REFINEMENT
REMARK 3 PDB ENTRY : NULL
REMARK 3 REFINEMENT SPACE : REAL
REMARK 3 REFINEMENT PROTOCOL : FLEXIBLE FIT
REMARK 3 REFINEMENT TARGET : NULL
REMARK 3 OVERALL ANISOTROPIC B VALUE : NULL
REMARK 3
REMARK 3 FITTING PROCEDURE : NULL
REMARK 3
REMARK 3 EM IMAGE RECONSTRUCTION STATISTICS
REMARK 3 NOMINAL PIXEL SIZE (ANGSTROMS) : NULL
REMARK 3 ACTUAL PIXEL SIZE (ANGSTROMS) : NULL
REMARK 3 EFFECTIVE RESOLUTION (ANGSTROMS) : 2.570
REMARK 3 NUMBER OF PARTICLES : 497555
REMARK 3 CTF CORRECTION METHOD : PHASE FLIPPING AND AMPLITUDE
REMARK 3 CORRECTION
REMARK 3
REMARK 3 EM RECONSTRUCTION MAGNIFICATION CALIBRATION: NULL
REMARK 3
REMARK 3 OTHER DETAILS: NULL
REMARK 4
REMARK 4 8DNZ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11
REMARK 100
REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 16-JUL-22.
REMARK 100 THE DEPOSITION ID IS D_1000266965.
REMARK 245
REMARK 245 EXPERIMENTAL DETAILS
REMARK 245 RECONSTRUCTION METHOD : SINGLE PARTICLE
REMARK 245 SPECIMEN TYPE : NULL
REMARK 245
REMARK 245 ELECTRON MICROSCOPE SAMPLE
REMARK 245 SAMPLE TYPE : PARTICLE
REMARK 245 PARTICLE TYPE : POINT
REMARK 245 NAME OF SAMPLE : A HUMAN-YEAST CHIMERIC SEC
REMARK 245 COMPLEX TREATED WITH APRATOXIN F
REMARK 245 SAMPLE CONCENTRATION (MG ML-1) : 10.00
REMARK 245 SAMPLE SUPPORT DETAILS : NULL
REMARK 245 SAMPLE VITRIFICATION DETAILS : BLOT FOR 4 SECONDS BEFORE
REMARK 245 PLUNGING
REMARK 245 SAMPLE BUFFER : NULL
REMARK 245 PH : 7.50
REMARK 245 SAMPLE DETAILS : NULL
REMARK 245
REMARK 245 DATA ACQUISITION
REMARK 245 DATE OF EXPERIMENT : NULL
REMARK 245 NUMBER OF MICROGRAPHS-IMAGES : NULL
REMARK 245 TEMPERATURE (KELVIN) : NULL
REMARK 245 MICROSCOPE MODEL : FEI TITAN KRIOS
REMARK 245 DETECTOR TYPE : GATAN K3 (6K X 4K)
REMARK 245 MINIMUM DEFOCUS (NM) : 800.00
REMARK 245 MAXIMUM DEFOCUS (NM) : 1600.00
REMARK 245 MINIMUM TILT ANGLE (DEGREES) : NULL
REMARK 245 MAXIMUM TILT ANGLE (DEGREES) : NULL
REMARK 245 NOMINAL CS : 2.70
REMARK 245 IMAGING MODE : BRIGHT FIELD
REMARK 245 ELECTRON DOSE (ELECTRONS NM**-2) : 5000.00
REMARK 245 ILLUMINATION MODE : FLOOD BEAM
REMARK 245 NOMINAL MAGNIFICATION : 81000
REMARK 245 CALIBRATED MAGNIFICATION : NULL
REMARK 245 SOURCE : FIELD EMISSION GUN
REMARK 245 ACCELERATION VOLTAGE (KV) : 300
REMARK 245 IMAGING DETAILS : NULL
REMARK 247
REMARK 247 ELECTRON MICROSCOPY
REMARK 247 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM ELECTRON
REMARK 247 MICROSCOPY DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE
REMARK 247 THAT CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES
REMARK 247 ON THESE RECORDS ARE MEANINGLESS EXCEPT FOR THE CALCULATION
REMARK 247 OF THE STRUCTURE FACTORS.
REMARK 300
REMARK 300 BIOMOLECULE: 1
REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM
REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN
REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON
REMARK 300 BURIED SURFACE AREA.
REMARK 350
REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN
REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE
REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS
REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND
REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN.
REMARK 350
REMARK 350 BIOMOLECULE: 1
REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TETRAMERIC
REMARK 350 APPLY THE FOLLOWING TO CHAINS: B, C, A, D
REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000
REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000
REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 465
REMARK 465 MISSING RESIDUES
REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE
REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN
REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.)
REMARK 465
REMARK 465 M RES C SSSEQI
REMARK 465 MET B 1
REMARK 465 ASP B 2
REMARK 465 GLN B 3
REMARK 465 VAL B 4
REMARK 465 MET B 5
REMARK 465 GLY B 67
REMARK 465 GLY B 68
REMARK 465 MET C 1
REMARK 465 PRO C 2
REMARK 465 GLY C 3
REMARK 465 PRO C 4
REMARK 465 THR C 5
REMARK 465 PRO C 6
REMARK 465 SER C 7
REMARK 465 GLY C 8
REMARK 465 THR C 9
REMARK 465 ASN C 10
REMARK 465 VAL C 11
REMARK 465 GLY C 12
REMARK 465 SER C 13
REMARK 465 SER C 14
REMARK 465 GLY C 15
REMARK 465 ARG C 16
REMARK 465 SER C 17
REMARK 465 PRO C 18
REMARK 465 SER C 19
REMARK 465 LYS C 20
REMARK 465 ALA C 21
REMARK 465 VAL C 22
REMARK 465 ALA C 23
REMARK 465 ALA C 24
REMARK 465 ARG C 25
REMARK 465 ALA C 26
REMARK 465 ALA C 27
REMARK 465 GLY C 28
REMARK 465 SER C 29
REMARK 465 THR C 30
REMARK 465 VAL C 31
REMARK 465 ARG C 32
REMARK 465 GLN C 33
REMARK 465 ARG C 34
REMARK 465 LYS C 35
REMARK 465 ASN C 36
REMARK 465 ALA C 37
REMARK 465 SER C 38
REMARK 465 CYS C 39
REMARK 465 GLY C 40
REMARK 465 THR C 41
REMARK 465 ARG C 42
REMARK 465 SER C 43
REMARK 465 ALA C 44
REMARK 465 GLY C 45
REMARK 465 ARG C 46
REMARK 465 THR C 47
REMARK 465 THR C 48
REMARK 465 SER C 49
REMARK 465 ALA C 50
REMARK 465 GLY C 51
REMARK 465 THR C 52
REMARK 465 GLY C 53
REMARK 465 GLY C 54
REMARK 465 MET C 55
REMARK 465 TRP C 56
REMARK 465 ARG C 57
REMARK 465 PHE C 58
REMARK 465 TYR C 59
REMARK 465 THR C 60
REMARK 465 GLU C 61
REMARK 465 ASP C 62
REMARK 465 SER C 63
REMARK 465 PRO C 64
REMARK 465 MET A 1
REMARK 465 ALA A 2
REMARK 465 ASP A 326
REMARK 465 THR A 327
REMARK 465 SER A 328
REMARK 465 SER A 329
REMARK 465 GLY A 330
REMARK 465 GLY A 331
REMARK 465 PRO A 332
REMARK 465 ALA A 333
REMARK 465 GLY A 469
REMARK 465 SER A 470
REMARK 465 MET A 471
REMARK 465 GLY A 472
REMARK 465 ALA A 473
REMARK 465 LEU A 474
REMARK 465 LEU A 475
REMARK 465 PHE A 476
REMARK 470
REMARK 470 MISSING ATOM
REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER;
REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER;
REMARK 470 I=INSERTION CODE):
REMARK 470 M RES CSSEQI ATOMS
REMARK 470 GLN B 6 CG CD OE1 NE2
REMARK 470 GLU B 9 CG CD OE1 OE2
REMARK 470 ARG B 12 CG CD NE CZ NH1 NH2
REMARK 470 ILE A 3 CG1 CG2 CD1
REMARK 470 PHE A 12 CG CD1 CD2 CE1 CE2 CZ
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT
REMARK 500
REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT.
REMARK 500
REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE
REMARK 500 OD2 ASP A 139 OG SER A 141 2.18
REMARK 500
REMARK 500 REMARK: NULL
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: TORSION ANGLES
REMARK 500
REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS:
REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER;
REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE).
REMARK 500
REMARK 500 STANDARD TABLE:
REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2)
REMARK 500
REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI-
REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400
REMARK 500
REMARK 500 M RES CSSEQI PSI PHI
REMARK 500 SER A 56 52.47 -94.61
REMARK 500 MET A 77 35.83 -98.49
REMARK 500 PHE A 312 58.40 -95.18
REMARK 500 SER A 408 55.91 -93.66
REMARK 500 SER A 443 -174.58 80.27
REMARK 500
REMARK 500 REMARK: NULL
REMARK 900
REMARK 900 RELATED ENTRIES
REMARK 900 RELATED ID: EMD-27585 RELATED DB: EMDB
REMARK 900 CRYO-EM STRUCTURE OF THE HUMAN SEC61 COMPLEX INHIBITED BY APRATOXIN
REMARK 900 F
DBREF 8DNZ B 1 68 UNP P60059 SC61G_HUMAN 1 68
DBREF 8DNZ C 1 96 UNP P60468 SC61B_HUMAN 1 96
DBREF 8DNZ A 1 476 UNP P61619 S61A1_HUMAN 1 476
DBREF 8DNZ D 1 5 PDB 8DNZ 8DNZ 1 5
SEQADV 8DNZ TYR A 263 UNP P61619 VAL 263 CONFLICT
SEQADV 8DNZ GLU A 264 UNP P61619 ASP 264 ENGINEERED MUTATION
SEQADV 8DNZ ARG A 268 UNP P61619 LYS 268 ENGINEERED MUTATION
SEQADV 8DNZ THR A 270 UNP P61619 ALA 270 ENGINEERED MUTATION
SEQADV 8DNZ LYS A 271 UNP P61619 ARG 271 ENGINEERED MUTATION
SEQADV 8DNZ VAL A 272 UNP P61619 TYR 272 ENGINEERED MUTATION
SEQADV 8DNZ ILE A 276 UNP P61619 TYR 276 ENGINEERED MUTATION
SEQADV 8DNZ GLY A 277 UNP P61619 ASN 277 ENGINEERED MUTATION
SEQADV 8DNZ ILE A 278 UNP P61619 THR 278 ENGINEERED MUTATION
SEQADV 8DNZ PRO A 387 UNP P61619 ALA 387 CONFLICT
SEQADV 8DNZ ARG A 388 UNP P61619 LYS 388 CONFLICT
SEQADV 8DNZ ILE A 390 UNP P61619 VAL 390 CONFLICT
SEQADV 8DNZ PHE A 394 UNP P61619 LEU 394 ENGINEERED MUTATION
SEQADV 8DNZ ASP A 396 UNP P61619 GLU 396 CONFLICT
SEQADV 8DNZ GLY A 398 UNP P61619 GLN 398 CONFLICT
SEQADV 8DNZ ILE A 401 UNP P61619 MET 401 ENGINEERED MUTATION
SEQADV 8DNZ ASN A 402 UNP P61619 ARG 402 ENGINEERED MUTATION
SEQADV 8DNZ LYS A 404 UNP P61619 HIS 404 ENGINEERED MUTATION
SEQADV 8DNZ ILE A 409 UNP P61619 MET 409 ENGINEERED MUTATION
SEQADV 8DNZ TYR A 410 UNP P61619 VAL 410 ENGINEERED MUTATION
SEQADV 8DNZ ARG A 411 UNP P61619 HIS 411 ENGINEERED MUTATION
SEQADV 8DNZ LYS A 414 UNP P61619 ASN 414 CONFLICT
SEQADV 8DNZ LYS A 415 UNP P61619 ARG 415 CONFLICT
SEQADV 8DNZ ILE A 416 UNP P61619 TYR 416 CONFLICT
SEQRES 1 B 68 MET ASP GLN VAL MET GLN PHE VAL GLU PRO SER ARG GLN
SEQRES 2 B 68 PHE VAL LYS ASP SER ILE ARG LEU VAL LYS ARG CYS THR
SEQRES 3 B 68 LYS PRO ASP ARG LYS GLU PHE GLN LYS ILE ALA MET ALA
SEQRES 4 B 68 THR ALA ILE GLY PHE ALA ILE MET GLY PHE ILE GLY PHE
SEQRES 5 B 68 PHE VAL LYS LEU ILE HIS ILE PRO ILE ASN ASN ILE ILE
SEQRES 6 B 68 VAL GLY GLY
SEQRES 1 C 96 MET PRO GLY PRO THR PRO SER GLY THR ASN VAL GLY SER
SEQRES 2 C 96 SER GLY ARG SER PRO SER LYS ALA VAL ALA ALA ARG ALA
SEQRES 3 C 96 ALA GLY SER THR VAL ARG GLN ARG LYS ASN ALA SER CYS
SEQRES 4 C 96 GLY THR ARG SER ALA GLY ARG THR THR SER ALA GLY THR
SEQRES 5 C 96 GLY GLY MET TRP ARG PHE TYR THR GLU ASP SER PRO GLY
SEQRES 6 C 96 LEU LYS VAL GLY PRO VAL PRO VAL LEU VAL MET SER LEU
SEQRES 7 C 96 LEU PHE ILE ALA SER VAL PHE MET LEU HIS ILE TRP GLY
SEQRES 8 C 96 LYS TYR THR ARG SER
SEQRES 1 A 476 MET ALA ILE LYS PHE LEU GLU VAL ILE LYS PRO PHE CYS
SEQRES 2 A 476 VAL ILE LEU PRO GLU ILE GLN LYS PRO GLU ARG LYS ILE
SEQRES 3 A 476 GLN PHE LYS GLU LYS VAL LEU TRP THR ALA ILE THR LEU
SEQRES 4 A 476 PHE ILE PHE LEU VAL CYS CYS GLN ILE PRO LEU PHE GLY
SEQRES 5 A 476 ILE MET SER SER ASP SER ALA ASP PRO PHE TYR TRP MET
SEQRES 6 A 476 ARG VAL ILE LEU ALA SER ASN ARG GLY THR LEU MET GLU
SEQRES 7 A 476 LEU GLY ILE SER PRO ILE VAL THR SER GLY LEU ILE MET
SEQRES 8 A 476 GLN LEU LEU ALA GLY ALA LYS ILE ILE GLU VAL GLY ASP
SEQRES 9 A 476 THR PRO LYS ASP ARG ALA LEU PHE ASN GLY ALA GLN LYS
SEQRES 10 A 476 LEU PHE GLY MET ILE ILE THR ILE GLY GLN SER ILE VAL
SEQRES 11 A 476 TYR VAL MET THR GLY MET TYR GLY ASP PRO SER GLU MET
SEQRES 12 A 476 GLY ALA GLY ILE CYS LEU LEU ILE THR ILE GLN LEU PHE
SEQRES 13 A 476 VAL ALA GLY LEU ILE VAL LEU LEU LEU ASP GLU LEU LEU
SEQRES 14 A 476 GLN LYS GLY TYR GLY LEU GLY SER GLY ILE SER LEU PHE
SEQRES 15 A 476 ILE ALA THR ASN ILE CYS GLU THR ILE VAL TRP LYS ALA
SEQRES 16 A 476 PHE SER PRO THR THR VAL ASN THR GLY ARG GLY MET GLU
SEQRES 17 A 476 PHE GLU GLY ALA ILE ILE ALA LEU PHE HIS LEU LEU ALA
SEQRES 18 A 476 THR ARG THR ASP LYS VAL ARG ALA LEU ARG GLU ALA PHE
SEQRES 19 A 476 TYR ARG GLN ASN LEU PRO ASN LEU MET ASN LEU ILE ALA
SEQRES 20 A 476 THR ILE PHE VAL PHE ALA VAL VAL ILE TYR PHE GLN GLY
SEQRES 21 A 476 PHE ARG TYR GLU LEU PRO ILE ARG SER THR LYS VAL ARG
SEQRES 22 A 476 GLY GLN ILE GLY ILE TYR PRO ILE LYS LEU PHE TYR THR
SEQRES 23 A 476 SER ASN ILE PRO ILE ILE LEU GLN SER ALA LEU VAL SER
SEQRES 24 A 476 ASN LEU TYR VAL ILE SER GLN MET LEU SER ALA ARG PHE
SEQRES 25 A 476 SER GLY ASN LEU LEU VAL SER LEU LEU GLY THR TRP SER
SEQRES 26 A 476 ASP THR SER SER GLY GLY PRO ALA ARG ALA TYR PRO VAL
SEQRES 27 A 476 GLY GLY LEU CYS TYR TYR LEU SER PRO PRO GLU SER PHE
SEQRES 28 A 476 GLY SER VAL LEU GLU ASP PRO VAL HIS ALA VAL VAL TYR
SEQRES 29 A 476 ILE VAL PHE MET LEU GLY SER CYS ALA PHE PHE SER LYS
SEQRES 30 A 476 THR TRP ILE GLU VAL SER GLY SER SER PRO ARG ASP ILE
SEQRES 31 A 476 ALA LYS GLN PHE LYS ASP GLN GLY MET VAL ILE ASN GLY
SEQRES 32 A 476 LYS ARG GLU THR SER ILE TYR ARG GLU LEU LYS LYS ILE
SEQRES 33 A 476 ILE PRO THR ALA ALA ALA PHE GLY GLY LEU CYS ILE GLY
SEQRES 34 A 476 ALA LEU SER VAL LEU ALA ASP PHE LEU GLY ALA ILE GLY
SEQRES 35 A 476 SER GLY THR GLY ILE LEU LEU ALA VAL THR ILE ILE TYR
SEQRES 36 A 476 GLN TYR PHE GLU ILE PHE VAL LYS GLU GLN SER GLU VAL
SEQRES 37 A 476 GLY SER MET GLY ALA LEU LEU PHE
SEQRES 1 D 5 T69 0A1 MAA IML MAA
HET T69 D 1 55
HET 0A1 D 2 24
HET MAA D 3 13
HET IML D 4 22
HET MAA D 5 13
HETNAM T69 (2E)-3-{(2R,4S)-2-[(2S,3S,5S,7S)-3,7-DIHYDROXY-5,8,8-
HETNAM 2 T69 TRIMETHYLNONAN-2-YL]-1,3-THIAZOLIDIN-4-YL}-2-
HETNAM 3 T69 METHYLPROP-2-ENOIC ACID
HETNAM 0A1 O-METHYL-L-TYROSINE
HETNAM MAA N-METHYL-L-ALANINE
HETNAM IML N-METHYL-ISOLEUCINE
FORMUL 4 T69 C19 H35 N O4 S
FORMUL 4 0A1 C10 H13 N O3
FORMUL 4 MAA 2(C4 H9 N O2)
FORMUL 4 IML C7 H15 N O2
HELIX 1 AA1 PHE B 7 CYS B 25 1 19
HELIX 2 AA2 ASP B 29 VAL B 66 1 38
HELIX 3 AA3 GLY C 69 SER C 96 1 28
HELIX 4 AA4 LYS A 4 ILE A 9 1 6
HELIX 5 AA5 ILE A 9 VAL A 14 1 6
HELIX 6 AA6 GLN A 27 CYS A 46 1 20
HELIX 7 AA7 PHE A 62 ARG A 66 5 5
HELIX 8 AA8 ILE A 81 ALA A 97 1 17
HELIX 9 AA9 THR A 105 THR A 134 1 30
HELIX 10 AB1 ASP A 139 GLY A 144 1 6
HELIX 11 AB2 GLY A 144 LYS A 171 1 28
HELIX 12 AB3 SER A 177 SER A 197 1 21
HELIX 13 AB4 GLY A 211 ARG A 223 1 13
HELIX 14 AB5 LYS A 226 TYR A 235 1 10
HELIX 15 AB6 ASN A 241 GLY A 260 1 20
HELIX 16 AB7 ASN A 288 PHE A 312 1 25
HELIX 17 AB8 ASN A 315 GLY A 322 1 8
HELIX 18 AB9 GLY A 340 LEU A 345 1 6
HELIX 19 AC1 SER A 350 ASP A 357 1 8
HELIX 20 AC2 ASP A 357 GLU A 381 1 25
HELIX 21 AC3 SER A 386 GLY A 398 1 13
HELIX 22 AC4 ILE A 409 LEU A 438 1 30
HELIX 23 AC5 GLY A 442 VAL A 468 1 27
SHEET 1 AA1 2 LYS C 67 VAL C 68 0
SHEET 2 AA1 2 GLU A 18 ILE A 19 1 O GLU A 18 N VAL C 68
SHEET 1 AA2 2 THR A 200 ASN A 202 0
SHEET 2 AA2 2 MET A 207 PHE A 209 -1 O GLU A 208 N VAL A 201
SHEET 1 AA3 3 ILE A 276 LYS A 282 0
SHEET 2 AA3 3 ARG A 262 SER A 269 -1 N TYR A 263 O ILE A 281
SHEET 3 AA3 3 MET A 399 ILE A 401 -1 O VAL A 400 N ARG A 268
SHEET 1 AA4 2 THR A 323 SER A 325 0
SHEET 2 AA4 2 TYR A 336 GLY A 339 -1 O VAL A 338 N THR A 323
LINK C48 T69 D 1 N 0A1 D 2 1555 1555 1.41
LINK O02 T69 D 1 C MAA D 5 1555 1555 1.37
LINK C 0A1 D 2 N MAA D 3 1555 1555 1.42
LINK C MAA D 3 N IML D 4 1555 1555 1.43
LINK C IML D 4 N MAA D 5 1555 1555 1.42
CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 1.000000 0.000000 0.000000 0.00000
SCALE2 0.000000 1.000000 0.000000 0.00000
SCALE3 0.000000 0.000000 1.000000 0.00000